• Mitsuyoshi Ota, Kenji Tatsumi, Hirokazu Suwa, Jun Watanabe, Kazuteru Watanabe, Shunichi Osada, Kuniya Tanaka, Fujii Shoichi, Yasushi Ichikawa, Chikara Kunisaki, and Itaru Endo.
• Hepato Gastroenterol. 2014 Jun 1; 61 (132): 1008-13.

UnlabelledBACKGROUND/Aims: To determine the effect of the pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine.MethodologyColorectal cancer patients scheduled for capecitabine chemotherapy as adjuvant setting were randomly assigned to with or without concurrent oral pyridoxine (60 mg/d) groups. Patients were monitored whether being a development of National Cancer Institute Common Toxicity Criteria grade 2 or worse HFS until chemotherapy ended.ResultsSixty patients were enrolled in this study. Relative dose intensity was 89.5% in total. The median number of chemotherapy cycles to grade 2 or worse HFS was four in both groups. Grade 2 or worse HES developed in 18 (60.0%) of 30 control patients and in 18 (60.0%) of 30 pyridoxine patients. The cumulative dose of capecitabine to grade 2 or worse HFS was not different between the two groups.ConclusionsPyridoxine is not effective in prevention of capecitabine-associated HFS.

33 keywords...

hide…